Safety and Pharmacodynamic Study of CD-NP

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

The primary objective of this study is to establish the safety of CD-NP in normal human volunteers.

Phase 1

Nile Therapeutics